CDP-Choline for Health & Longevity - Quick Reference Sheet

CDP-Choline for Health & Longevity

Created on 09/18/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A molecule the body already makes, sold as a prescription medicine in several countries and as a supplement elsewhere. The strongest human signal is memory in adults whose recall has slipped with age, from small, short, often poor-quality studies. Side effects are mild and uncommon. Much of the supporting literature comes from the companies that sell it. (Full Review)

Protocol

Standard supplement regimen
250–500 mg once daily
With breakfast; 500 mg for 12 weeks in the healthy-ageing memory trial
Clinical European regimen
500 mg twice daily
Totalling 1,000 mg; the dose used in most cognitive trials
Best time of day
Morning, with breakfast
Alerting effects appear within hours; evening dosing is the most common reported cause of insomnia
Time to effect
Memory
12 weeks
The realistic assessment window; the point at which controlled-trial memory endpoints read out
Attention and reaction time
Hours to 28 days
From a single 28-day controlled trial; the attention signal is unreplicated in adults
Brain energy reserves
6 weeks
Six weeks of 500 or 2,000 mg daily raised frontal-lobe energy stores on brain imaging

Benefits

Contraindications
  • Documented hypersensitivity to citicoline or its excipients
  • Hypertonia of the parasympathetic nervous system
  • Trimethylaminuria (FMO3 deficiency)
  • Pregnancy and breastfeeding
  • Concurrent meclofenoxate
  • Chronic kidney disease stage 4 or worse (below 30 mL/min/1.73 m²)
  • Symptomatic bradycardia (below 50 bpm) or untreated orthostatic hypotension
Key Interactions
  • Levodopa and carbidopa-levodopa (Sinemet, Madopar)
  • Cholinesterase inhibitors (donepezil, rivastigmine, galantamine)
  • Central anticholinergics (oxybutynin, scopolamine, diphenhydramine, benztropine)
  • Other choline donors (alpha-GPC, choline bitartrate, phosphatidylcholine, lecithin)
  • Racetams (piracetam, aniracetam, phenylpiracetam)
  • Stimulants (caffeine, methylphenidate, modafinil)
  • Blood-pressure and heart-rate-lowering medicines (beta-blockers such as metoprolol, calcium channel blockers such as verapamil and diltiazem)

Risk & Side Effects

  • Medium: Gastrointestinal intolerance
  • Low: Headache; insomnia and restlessness; transient hypotension and bradycardia; higher study discontinuation in depression trials
  • Speculative: Trimethylamine N-oxide generation from the choline component

Monitoring

Marker Target Why
Plasma free choline 8–12 µmol/L Shows whether supplemental choline is needed at all
Homocysteine < 8 µmol/L Choline and folate share the methylation pathway that clears it
Trimethylamine N-oxide < 5 µmol/L Tracks gut conversion of choline into a clot-promoting metabolite
Blood pressure < 120/80 mmHg Detects the hypotension reported at high doses
Resting heart rate 55–70 bpm Detects the bradycardia reported with high-dose injected use
Alanine aminotransferase 10–26 U/L (men), 8–22 U/L (women) Choline adequacy protects against fat accumulation in the liver
Computerised cognitive battery composite No established target; track change from the individual's own baseline Gives an objective read on whether memory is actually responding

Cadence: Blood pressure and pulse at baseline and 4 weeks, cognitive battery at 12 weeks, full fasting panel at 6 to 12 months thereafter

Qualitative Assessment

  • Subjective clarity of recall for names, faces and recent conversations
  • Sustained attention during long cognitively demanding tasks
  • Mental fatigue late in the working day
  • Sleep onset latency, which flags dosing that is too late in the day
  • Digestive comfort in the first fortnight, the window in which intolerance appears
  • Motivation and drive, which the dopaminergic mechanism would plausibly touch